Updated just now. Six pages so far. The breadth of destruction is staggering.
But the bill from Sen. Cassidy has stalled in Congress. Despite bipartisan sponsors in the senate, it hasn’t received a committee hearing or a vote, as lawmakers focus on other priorities and broader partisan fights over health spending.
The second story in my series on barriers to hepatitis C elimination in the U.S. focuses on legislative hurdles. A bill would do what other countries and some states already do: negotiate with drug companies to lower treatment costs and expand access to those who need it most.
The Trump admin terminated NIH grant funding for a long-running research network that studied HIV in adolescents.
One of the immediate impacts of this is a cancelled study to examine whether an antibiotic currently only approved for men to prevent STDs can also work in women.